Huons Biopharma's 'Liztox' Completes Phase 2 Clinical Trial for Square Jaw

Huons Biopharma Botulinum Toxin 'Liztox' (Photo by Huons Biopharma)

[Asia Economy Reporter Lee Chun-hee] Huons Bio Pharma, a subsidiary of Huons Global, announced on the 4th that it has successfully completed the domestic Phase 2 clinical trial for the improvement of benign masseter hypertrophy (square jaw) using the botulinum toxin 'Liztox' (export name 'Hutox').

Huons Bio Pharma explained that through this Phase 2 trial, the clinical efficacy of Liztox in improving benign masseter hypertrophy was confirmed in adults requiring treatment. They also reported that no significant safety issues were observed in comparison with existing botulinum toxin type A formulations.

Huons Bio Pharma stated, "In the field of benign masseter hypertrophy improvement, botulinum toxin can be used as a minimally invasive method involving a relatively simple procedure of direct injection into the masseter muscle, potentially replacing conservative and surgical treatments." They added, "We expect Liztox's competitiveness to be further enhanced after obtaining the indication."

Huons Bio Pharma plans to immediately begin preparations for Phase 3 clinical trials. The expected timing for indication approval is the second half of 2024.

A Huons Bio Pharma official said, "We are focusing on expanding the indications and dosages of Liztox to meet the demands of the botulinum toxin market. The Phase 3 clinical trial for treating upper limb spasticity after stroke is progressing smoothly, and with the launch of 50-unit and 200-unit products this year, we will have a total of three lineups (50 units, 100 units, and 200 units), which will significantly strengthen our competitiveness in the domestic market."

This content was produced with the assistance of AI translation services.